You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Vericiguat - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for vericiguat and what is the scope of patent protection?

Vericiguat is the generic ingredient in one branded drug marketed by Merck Sharp Dohme and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vericiguat has two hundred and ten patent family members in forty-nine countries.

One supplier is listed for this compound.

Summary for vericiguat
International Patents:210
US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 52
Clinical Trials: 19
Patent Applications: 282
What excipients (inactive ingredients) are in vericiguat?vericiguat excipients list
DailyMed Link:vericiguat at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for vericiguat
Generic Entry Date for vericiguat*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for vericiguat

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Heart, Lung, and Blood Institute (NHLBI)Phase 4
University of Colorado, DenverPhase 4
Memorial Sloan Kettering Cancer CenterPhase 2

See all vericiguat clinical trials

Pharmacology for vericiguat

US Patents and Regulatory Information for vericiguat

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-002 Jan 19, 2021 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-003 Jan 19, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-002 Jan 19, 2021 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-002 Jan 19, 2021 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for vericiguat

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Bayer AG Verquvo vericiguat EMEA/H/C/005319
Treatment of symptomatic chronic heart failure
Authorised no no no 2021-07-16
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for vericiguat

Country Patent Number Title Estimated Expiration
Chile 2012003226 Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas. ⤷  Try a Trial
Eurasian Patent Organization 030735 ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОГО СКЛЕРОЗА (SSc) (USE OF sGC STIMULATORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc)) ⤷  Try a Trial
New Zealand 724215 Method for producing substituted 5-fluoro-1h-pyrazolopyridines ⤷  Try a Trial
Serbia 54704 SUPSTITUISANI 5-FLUOR-1H-PIRAZOLOPIRIDINI I NJIHOVA PRIMENA (SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND USE THEREOF) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for vericiguat

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2576547 PA2021518,C2576547 Lithuania ⤷  Try a Trial PRODUCT NAME: VERICIGUATAS IR JO DRUSKOS, SOLVATAI IR DRUSKU SOLVATAI ; REGISTRATION NO/DATE: EU/1/21/1561 20210716
2576547 2190031-1 Sweden ⤷  Try a Trial PRODUCT NAME: VERICIGUAT AND ITS SALTS, SOLVATES AND SOLVATES OF THE SALTS; REG. NO/DATE: EU/1/21/1561 20210720
2576547 132021000000137 Italy ⤷  Try a Trial PRODUCT NAME: VERICIGUAT(VERQUVO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/21/1561, 20210720
2576547 PA2021518 Lithuania ⤷  Try a Trial PRODUCT NAME: VERICIGUATAS IR JO DRUSKOS, SOLVATAI IR DRUSKU SOLVATAI ; REGISTRATION NO/DATE: EU/1/21/1561 20210716
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.